// immunotherapies

About
Immunotherapies

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

// immunotherapies

Our R&D Pipeline

01

TriMix
Lipid Nanoparticles
Oncolysis
Tumor microenvironment modulating technology

LEARN MORE
01

Technology

Technology
02

Melanoma
HPV+ cancer
Kidney cancer
Other indications

LEARN MORE
02

Immunostimulation

Immunostimulation
03

eTheRNA is developing mRNA-based products mimicking the action of oncolytic viruses.

LEARN MORE
03

Oncolytic mRNA

Oncolytic mRNA
04

eTheRNA has formed a consortium with North American and European partners to access tools to develop a novel mRNA vaccine against CoV-19.

LEARN MORE
04

Infectious Disease

Infectious Disease
// immunotherapies

Our Partnerships

Technology Partnering
eTheRNA intends to build high-value strategic collaborations for exploring the benefits of the TriMix technology in various disease areas.





Product
Partnering
eTheRNA seeks collaborative partnerships with pharma companies that enable us to develop - and ultimately also to commercialize - differentiated TriMix-based immunotherapies on either a risk-sharing or out-licensing basis.


mRNA Production Partnering
eTheRNA operates a cGMP accredited mRNA production facility in Niel, Belgium and currently focusses on producing mRNA-constructs exclusively for its own development plans. However as the clinical development program advances, the Company has the option to expand capacity and explore strategic partnerships.

// eTheRNA

WE'D LIKE TO HEAR FROM YOU

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk